{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099878","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.639659+00:00","generated_at":"2026-05-17T23:25:47.732362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amarin Q2 net loss $14.1M; signs European licensing deal with Recordati, plans restructuring","bullets":["Q2 net loss of $14.1M ($0.03 per share) vs. $1.5M net income in Q2 2024.","Total net revenue $72.7M (+8% YoY); licensing revenue up 31% on Recordati upfront.","Signed exclusive European licensing agreement with Recordati for VAZKEPA in 59 countries.","Global restructuring expected to deliver $70M in operating expense savings over 12 months.","Cash $298.7M, debt-free; U.S. product revenue down 17% to $36.5M, Europe up 85% to $6.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099878","json":"https://secwatch.observer/filing/0000950170-25-099878.json","markdown":"https://secwatch.observer/filing/0000950170-25-099878.md","text":"https://secwatch.observer/filing/0000950170-25-099878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017025099878/0000950170-25-099878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017025099878/amrn-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:25:47.732362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}